Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.18 USD | +0.54% | +3.18% | +6.14% |
Financials (USD)
Sales 2024 * | 955M | Sales 2025 * | 1.1B | Capitalization | 4.95B |
---|---|---|---|---|---|
Net income 2024 * | 368M | Net income 2025 * | 484M | EV / Sales 2024 * | 6.23 x |
Net Debt 2024 * | 1B | Net Debt 2025 * | 422M | EV / Sales 2025 * | 4.88 x |
P/E ratio 2024 * |
13
x | P/E ratio 2025 * |
9.56
x | Employees | 373 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.92% |
Latest transcript on Halozyme Therapeutics, Inc.
1 day | +0.59% | ||
1 week | +1.46% | ||
Current month | -4.28% | ||
1 month | -2.84% | ||
3 months | +12.06% | ||
6 months | +11.99% | ||
Current year | +5.36% |
Managers | Title | Age | Since |
---|---|---|---|
Helen Torley
CEO | Chief Executive Officer | 61 | 14-01-05 |
Nicole LaBrosse
DFI | Director of Finance/CFO | 41 | 14-12-31 |
Mark Snyder
CMP | Compliance Officer | 57 | 22-01-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Connie Matsui
BRD | Director/Board Member | 70 | 06-07-30 |
Chairman | 59 | 15-08-04 | |
Barbara Duncan
BRD | Director/Board Member | 59 | 23-02-02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.48% | 5 M€ | -1.80% | - | |
0.73% | 0 M€ | 0.00% | - | |
0.55% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 39.2 | +0.60% | 47 575 |
24-04-23 | 38.97 | +0.67% | 557,948 |
24-04-22 | 38.71 | +0.18% | 525,232 |
24-04-19 | 38.64 | +2.20% | 1,258,837 |
24-04-18 | 37.81 | -0.55% | 792,530 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.36% | 4.95B | |
-0.49% | 105B | |
+3.31% | 97.5B | |
+1.66% | 22.19B | |
-16.16% | 21.33B | |
-6.82% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |
- Stock Market
- Equities
- HALO Stock